• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The effect of measuring error on the results of therapeutic trials in advanced cancer.

作者信息

Moertel C G, Hanley J A

出版信息

Cancer. 1976 Jul;38(1):388-94. doi: 10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a.

DOI:10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a
PMID:947531
Abstract

In this study, 16 experienced oncologists each measured 12 simulated tumor masses employing their usual clinical methods. Unknown to the oncologists, two pairs of these tumors were identical in size. This permitted a total of 64 measurement comparisons of the same investigator measuring the same size mass and 1920 comparisons of different investigators measuring the same size mass. If a 50% reduction in the product of perpendicular diameters is accepted as a criterion, the objective response rate due to measuring error alone was 7.8% by the same investigator and 6.8% by different investigators. If a 25% reduction criterion is used, the respective "placebo" response rates were 19% and 25%. In the clinical setting it is recommended that the 50% reduction criterion be employed and that the investigator should anticipate an objective response rate of 5 to 10% due to human error in tumor measurement.

摘要

相似文献

1
The effect of measuring error on the results of therapeutic trials in advanced cancer.
Cancer. 1976 Jul;38(1):388-94. doi: 10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a.
2
Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop.年轻临床研究人员使用圆周测量法与标准卡尺测量法测量肺部和皮肤表面结节时的准确性和可重复性比较:美国癌症研究协会/美国临床肿瘤学会临床试验研讨会
J Clin Oncol. 2000 Jan;18(2):437-44. doi: 10.1200/JCO.2000.18.2.437.
3
Measuring response in solid tumors: unidimensional versus bidimensional measurement.实体瘤中反应的测量:一维测量与二维测量
J Natl Cancer Inst. 1999 Mar 17;91(6):523-8. doi: 10.1093/jnci/91.6.523.
4
A statistical simulation study finds discordance between WHO criteria and RECIST guideline.一项统计模拟研究发现,世界卫生组织(WHO)标准与实体瘤疗效评价标准(RECIST)指南之间存在不一致。
J Clin Epidemiol. 2004 Apr;57(4):358-65. doi: 10.1016/j.jclinepi.2003.07.015.
5
Computerized tomography brain scan tumor volume determinations. Sensitivity as an objective criterion of response to therapy.
J Neurosurg. 1990 Jun;72(6):872-8. doi: 10.3171/jns.1990.72.6.0872.
6
Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement.实体瘤疗效评估的变异性:测量所选病灶数量的影响。
Clin Cancer Res. 2003 Oct 1;9(12):4318-23.
7
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.晚期实体瘤的分子特征分析与基因匹配临床试验的患者预后:玛格丽特公主癌症中心IMPACT/COMPACT试验
Genome Med. 2016 Oct 25;8(1):109. doi: 10.1186/s13073-016-0364-2.
8
[Problems in evaluating the effects of cancer chemotherapy].
Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 1):297-301.
9
Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.关于:罗森塔尔·迪、格拉茨坦·埃。《我们有了一种治疗方法,但疾病是什么?》,《肿瘤学家》1996年;第1期。
Oncologist. 1997;2(1):59-61.
10
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.在绝经后激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者中,比较布帕利西布联合氟维司群与安慰剂联合氟维司群的疗效(BELLE-2):一项随机、双盲、安慰剂对照的3期试验。
Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.

引用本文的文献

1
The legend of the response evaluation criteria in solid tumors: A historical overview.实体瘤疗效评价标准的传奇:历史概述。
Cancer. 2025 Sep 1;131(17):e70064. doi: 10.1002/cncr.70064.
2
Developing, Analyzing, and Interpreting Outcome Assessments to Improve Endpoints in Infectious Diseases Clinical Research.开发、分析和解读结果评估以改善传染病临床研究中的终点指标。
Clin Infect Dis. 2025 Aug 6;81(Supplement_1):S4-S10. doi: 10.1093/cid/ciaf319.
3
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
重新定义新辅助化疗治疗高危软组织肉瘤的放射学反应:ISG-STS 1001随机临床试验的最终结果
ESMO Open. 2025 Mar;10(3):104299. doi: 10.1016/j.esmoop.2025.104299. Epub 2025 Mar 7.
4
Comparing quantitative imaging biomarker alliance volumetric CT classifications with RECIST response categories.比较定量成像生物标志物联盟的容积CT分类与RECIST反应类别。
Radiol Adv. 2025 Jan 6;2(1):umaf001. doi: 10.1093/radadv/umaf001. eCollection 2025 Jan.
5
Outcomes that matter to patients with cancer: living longer and living better.对癌症患者至关重要的结果:活得更长且活得更好。
EClinicalMedicine. 2024 Sep 11;76:102833. doi: 10.1016/j.eclinm.2024.102833. eCollection 2024 Oct.
6
Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer.使用正电子发射计算机断层扫描评估吉西他滨联合顺铂化疗对转移性膀胱癌的疗效
World J Clin Cases. 2023 Dec 26;11(36):8447-8457. doi: 10.12998/wjcc.v11.i36.8447.
7
A Scoring System for Predicting Neoadjuvant Chemotherapy Response in Primary High-Grade Bone Sarcomas: A Multicenter Study.原发性高级别骨肉瘤新辅助化疗反应预测的评分系统:一项多中心研究。
Orthop Surg. 2022 Oct;14(10):2499-2509. doi: 10.1111/os.13469. Epub 2022 Aug 26.
8
Imaging response assessment for oncology: An algorithmic approach.肿瘤学的影像反应评估:一种算法方法。
Eur J Radiol Open. 2022 Jun 7;9:100426. doi: 10.1016/j.ejro.2022.100426. eCollection 2022.
9
Deciphering radiological stable disease to immune checkpoint inhibitors.解析影像学稳定疾病对免疫检查点抑制剂的影响。
Ann Oncol. 2022 Aug;33(8):824-835. doi: 10.1016/j.annonc.2022.04.450. Epub 2022 May 6.
10
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.二十年回顾:实体瘤疗效评估标准(RECIST)作为实体瘤反应生物标志物——欧洲癌症研究与治疗组织(EORTC)影像组与欧洲肿瘤内科学会(ESOI)联合论文
Front Oncol. 2022 Jan 10;11:800547. doi: 10.3389/fonc.2021.800547. eCollection 2021.